We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPoolbeg Pharma Share News (POLB)

Share Price Information for Poolbeg Pharma (POLB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 11.45
Bid: 11.30
Ask: 11.60
Change: 0.20 (1.72%)
Spread: 0.30 (2.655%)
Open: 11.65
High: 11.80
Low: 11.80
Prev. Close: 11.60
POLB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Polar Capital assets up; Brooks Macdonald funds fall

Thu, 14th Apr 2022 21:36

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and Wednesday and not separately reported by Alliance News:

----------

Polar Capital Holdings PLC - London-based specialist active fund manager - Says assets under management rise 6.0% to GBP22.12 billion at March 31 year end, from GBP20.86 billion a year prior. Net subscriptions amount to GBP391 million. Market movements contribute GBP867 million.

----------

Brooks Macdonald Group PLC - London-based investment manager - Funds under management on March 31, end of third quarter, fall 3.9% to GBP16.7 billion from GBP17.3 billion on December 31.

----------

Jupiter Emerging & Frontier Income Trust PLC - investment trust focused on companies in emerging and frontier markets worldwide - Still intends to put forward wind up of company, providing shareholders with full cash exit, minus costs. Company had reviewed "number of proposals for rollover vehicle candidates and has concluded not to offer a rollover option".

----------

finnCap Group PLC - London-based stockbroker - Says revenue in year ended March 31 rises 12% to GBP52.4 million from GBP46.6 million. Says adjusted pretax profit to be in line with market expectations. Chief Executive Sam Smith commented: "Operating in a more complex equity market in H2, in particular following the tragic events in Ukraine, the finnCap Capital Markets team performed well delivering its second best-ever annual revenue performance and a result in line with our expectations."

----------

Pires Investment PLC - London-based technology-focused investor - Investee Pluto Digital PLC finalises audited accounts. As of September 30, Pluto's net assets amounted to GBP61 million, 9.5p per share. Pires Director Nicholas Lee says: "Pluto has made substantial progress in the DeFi, Metaverse and NFT sectors since its inception around 12 months ago. The audited NAV per share figure represents a significant increase compared to the price of the most recent funding round, however, in terms of market valuation, companies similar to Pluto can often trade at a multiple of NAV."

----------

Plaza Centers NV - property investor in India - Notes purchaser of site in Bangalore, India held by Plaza Centers 48%-owned investee Elbit Plaza India Real Estate Holdings Ltd purchased asset for EUR49 million. As of Wednesday, the buyer has made payments totalling EUR11.2 million, leaving EUR32.6 million remaining. Buyer, since 2019, has been unable to pay remaining amount. Buyer instead submits an informal non-binding proposal to purchase 100% of EPI's interest in asset and the completion of deal in exchange for payment of EUR13.6 million to EUR14.2 million, instead of the remaining payment. Plaza adds: "It will be clarified that the approval of the transaction is also subject to the approval of Elbit Imaging Ltd, which holds approximately 47.5% of EPI's issued and paid-up capital. The company estimates that as the contacts with the Purchaser will crystallized into a complete transaction, EPI is expected to recognize a capital gain of approximately EUR3.6-4.3 million."

----------

React Group PLC - South Derbyshire, England-based cleaning, hygiene and decontamination firm - Raises GBP5.5 million from placing of 458.3 million shares at 1.2 pence per share. Plans to use the proceeds to strengthen its balance sheet and to support its stated acquisition growth strategy and general working capital purposes.

----------

RTW Venture Fund Ltd - New York-based investor in life sciences, biopharmaceutical, and medical technology companies - Invests in LENZ Therapeutics, a late-stage clinical company developing innovative ophthalmic pharmaceutical products for vision improvement. LENZ enters into exclusive license agreement with Ji Xing Pharmaceuticals to develop and commercialise LNZ100 and LNZ101 treatment in Greater China. RTW's manager RTW Investments LP invests USD10 million in Lenz.

----------

Impact Healthcare REIT PLC - real estate investment trust focused on healthcare properties - Buys three care homes in and around Glasgow for GBP8.1 million.

----------

Midatech Pharma PLC - Cardiff-based drug delivery technology company - Receives notice from Nasdaq Stock Market LLC stating company is not in compliance with minimum bid requirement for continued listing on Nasdaq Capital Market. It requires minimum bid price of USD1 per share. Company's shares have not met minimum threshold for 30 successive days. Midatech explains: "The company has a grace period of 180 calendar days, or until 10 October 2022 to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the depositary shares must meet or exceed USD1.00 per share for at least 10 consecutive business days during the compliance period." Midatech then has access to additional grace period of 180 days but if it does not regain compliance then, it will receive notice its shares are subject to delisting.

----------

Poolbeg Pharma PLC - London-based pharmaceutical company – Says European Patent Office grants patent related to POLB 002, a dual antiviral prophylactic and therapeutic candidate.

----------

Vertu Motors PLC - Gateshead, England-based car dealership - Buys freehold and long leasehold interests in multi-franchise site located in Derby. Assets of the dealerships were acquired from Co-operative Group Motors Ltd. "A lease on the premises was granted to the group at the time of this purchase, with this lease due to expire in February 2026," Vertu says. Purchase completed on April 6 at cost of GBP7.1 million plus fees.

----------

Bens Creek Group PLC - London-based mining company focused in North America - Enters into coal sub-lease agreement with Star Ridge Land LLC. Star Ridge is the successor to G1 Mining LLC as lessee under their lease with Pocahontas Land Corp, on two assets in West Virginia. Bens Creek will pay Pocahontas a production royalty and also pay Star Ridge a minimum royalty per quarter, beginning 30 months after the April 11 effective date of sub-lease pact. After 42 months, Bens Creek pays Star Ridge an increased minimum royalty. Integrity Coal Sales Inc, an affiliate of Star Ridge, has the right and first option to purchase all coal mined and removed from the property. Star Ridge, within 10 working days of effective date, will receive options to buy GBP250,000 worth of Bens Creek shares at 93 pence each. "Bens Creek shall drill a minimum of three core holes on the property within twelve months of the effective date. The results of such core drilling shall be made available to Star Ridge," Bens Creek adds. "Bens Creek will use its best efforts to secure a mining permit upon the property and shall apply for a mining permit within twelve months."

----------

Anglo Asian Mining PLC - gold, copper and silver producer focused in Azerbaijan - Says first quarter gold output falls annually to 10,040 ounces from 11,907 ounces. Copper production falls to 568 tonnes from 638 tonnes. Silver production rises to 50,689 ounces from 35,365 ounces.

----------

Petrel Resources PLC - hydrocarbon explorer with interests in Iraq and Ghana - Says High Court injunction over the 32.1 million shares previously held by the Tamraz Group has been lifted.

----------

Oilex Ltd - Perth-based developer of natural gas assets - Signs letter of intent with US oilfield services giant Schlumberger NV for the supply by Schlumberger of hydraulic fracturing services, coiled tubing and nitrogen services and perforation services for the planned re-frac of the Cambay C-77H well in July. Company adds: "Due to the higher than anticipated C-77H re-frac costs caused by a global shortage of fraccing services and equipment, and the delayed start up of gas production on the Cambay field, Oilex plans to raise additional funds over the next approximate month." Also negotiates gas sales agreement for the sale of gas from Cambay.

----------

Trident Royalties PLC - Mining royalty and streaming company with projects in countries ranging from Peru to Canada - To receive USD3.8 million from Equinox Gold Corp. Equinox sells the Mercedes gold and silver mine in Mexico to Bear Creek Mining Corp. Mercedes forms part of gold offtake portfolio Trident acquired from funds managed by Orion Resource Partners for USD69.8 million in cash and shares. "Following the sale of the Mercedes Mine, the Premier offtake will remain in place over Greenstone, which has commenced construction with the first gold pour targeted for H1," Trident adds.

----------

SulNOx Group PLC - London-based supplier of fuel conditioners - Teams with Group PMS International for decarbonisation drive in Europe and North Africa. SulNOx adds: "PMS is a long established, Spanish multinational based in Barcelona, with subsidiary companies in Algeria and Morocco and business operations in Tunisia, Nigeria, Angola, Cameroon, Ghana and Senegal. As the first foreign company to create a distribution company in Algeria, PMS have more than 50 years' experience as a leader in commodity and specialty chemical distribution in the Magreb region."

----------

Nostrum Oil & Gas PLC - Amsterdam-headquartered oil and gas company with operations in Kazakhstan - Proposes restructure of USD725 million 8.0% senior notes due July 2022 and USD400 million 7.0% senior notes due February 2025. It has been in informal ad hoc with noteholders since May 2020, following oil price collapse in wake of Covid-19 pandemic. Says key features of restructuring include partial reinstatement of existing notes in form of new USD250.0 million and USD300.0 million senior unsecured notes, both maturing in June 2026. Remainder of existing notes converted to new shares. Anticipates noteholders will own just 89% of enlarged share capital.

----------

Oracle Power PLC - London-based power and natural resource project developer with projects focused on Pakistan - Says begins 2022 with "high activity across every dimension of our portfolio". Says Pakistan assets "moving through the gears" as company looks to grow commercial footprint. Forms joint-venture Oracle Energy Ltd to help bring "revolutionary potential of green hydrogen to the Pakistani market". JV to be 70%-funded by Kaheel Energy.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
14 Dec 2022 16:14

Poolbeg secures exclusive licence to possible obesity drug tech

(Sharecast News) - Infectious disease-focussed biopharmaceutical company Poolbeg Pharma has acquired an exclusive licence from AnaBio sister company InsuCaps, it announced on Wednesday, to use its patented microencapsulation and nanoencapsulation oral delivery technologies in metabolic syndrome-related diseases, including obesity, pre-diabetes and diabetes.

Read more
2 Dec 2022 19:33

TRADING UPDATES: Time Out eyes Riyadh; MTI Wireless wins deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued this week and not separately reported by Alliance News:

Read more
15 Nov 2022 17:25

Poolbeg Pharma wins funding for oral vaccine development

(Alliance News) - Poolbeg Pharma PLC on Tuesday said it has received funding from the Irish Government to improve the manufacturing, distribution and administration of its oral vaccines.

Read more
8 Nov 2022 13:06

Poolbeg announces 'breakthrough' in AI drug target programme

(Sharecast News) - Infectious disease pharmaceutical developer Poolbeg Pharma announced a "significant breakthrough" in its artificial intelligence (AI) programme with partner OneThree Biotech on Tuesday, through the discovery of novel drug targets for the treatment of respiratory syncytial virus (RSV).

Read more
8 Nov 2022 12:18

IN BRIEF: Poolbeg makes "significant breakthrough" in AI programme

Poolbeg Pharma PLC - London-based clinical stage infectious disease pharmaceutical company - Announces "significant breakthrough" in its artificial intelligence programme with its partner OneThree Biotech Inc, a New York-based drug discovery-focused firm. Says breakthrough is the discovery of novel drug targets for the treatment of respiratory syncytial virus. The identification of these targets allow for the final stages of the programme to start, Poolbeg explains. This will involve the identification of small molecule inhibitors to treat RSV infections. The team is "particularly excited", the firm says, as these include a range of targets for which there are known drugs with existing Phase I safety and tolerability data. Results are expected before the end of 2022.

Read more
4 Oct 2022 14:14

Poolbeg Pharma upbeat on US patent application progress

(Sharecast News) - Infectious disease pharmaceutical company Poolbeg Pharma updated the market on its intellectual property (IP) position around 'POLB 001' on Tuesday, which it described as a small molecule immunomodulator for the treatment of severe influenza.

Read more
4 Oct 2022 10:14

Poolbeg expects formal patent grant soon to treat hypercytokinemia

(Alliance News) - Poolbeg Pharma PLC on Tuesday said that the US Patent & Trademarks Office has indicated that its patent application concerning the use of POLB 001 and its homologues for the treatment of hypercytokinemia is allowable.

Read more
4 Oct 2022 08:46

LONDON MARKET OPEN: Stocks rise as market sentiment recovers

(Alliance News) - Stock prices in London opened sharply higher on Tuesday, lifted by more positive market sentiment following the UK government's tax U-turn, as well as some positive trading updates.

Read more
4 Oct 2022 07:52

LONDON BRIEFING: Pound, oil, gold up; Truss vows fiscal responsibility

(Alliance News) - Stocks in London are called higher on Tuesday, as the market watches closely for further clues regarding the UK's economic direction.

Read more
27 Sep 2022 06:59

IN BRIEF: Poolbeg Pharma teams up for Melioidosis vaccine

Poolbeg Pharma PLC - London-based pharmaceutical company - On Wednesday reported it a signed an in-license agreement for the development of a Melioidosis vaccine candidate with University College Dublin. Melioidosis is an infectious disease spread by a bacterium in contaminated soil or water. It has a minimum fatality rate of around 10% and no vaccine for the disease exists. Poolbeg's late preclinical stage vaccine candidate has the name POLB 003. It is being developed following several years of research.

Read more
21 Sep 2022 16:18

Poolbeg inks exclusive deal for melioidosis vaccine candidate

(Sharecast News) - Clinical-stage infectious disease pharmaceutical company Poolbeg Pharma has signed an exclusive licence agreement with University College Dublin (UCD), it announced on Wednesday, for a late preclinical-stage vaccine candidate for melioidosis.

Read more
6 Sep 2022 14:04

IN BRIEF: Poolbeg shares rises on narrowed loss, strong pipeline

Poolbeg Pharma PLC - London-based pharmaceutical company - In the six months ended June 30, narrows its pretax loss to GBP1.7 million from GBP2.3 million loss the year prior. Does not post a revenue figure, unchanged from the previous year. Research & development expenses rise to GBP657,000 from GBP414,000. Notes "significant" progress on POLB 001, its treatment for severe influenza. Expects outputs from its respiratory syncytial virus and influenza artificial intelligence programmes by the end of 2022 and the second quarter of 2023, respectively. Adds it has "strong financial resources available to progress its products and platforms."

Read more
20 Jul 2022 12:04

IN BRIEF: Poolbeg Pharma shares rise as first human trial begins

Poolbeg Pharma PLC - London-based pharmaceutical company - Receives approval to commence its Lipopolysaccharide human clinical trial for POLB 011, a drug that aims to treat severe influenza. The trial will formally start on Friday. It will assess POLB 011 in damping the immune response to lipopolysaccharide, which acts as a surrogate for the hyperinflammatory response associated with severe influenza. Initial results are expected in the final quarter of 2022. Poolbeg says at that point it intends to "rapidly" monetise by out-licensing and/or partnering with pharmaceutical and biotechnology companies for the drug's further development.

Read more
27 Jun 2022 10:47

Poolbeg Pharma AI model of respiratory syncytial virus starts analysis

(Alliance News) - Poolbeg Pharma PLC on Monday said its build and optimisation of an artificial intelligence model of respiratory syncytial virus data is complete.

Read more
27 May 2022 10:43

AIM WINNERS & LOSERS: Premier Miton advances; Advance Energy retreats

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.